The EU's Falsified Medicines Directive and APIs - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The EU's Falsified Medicines Directive and APIs
Siegfried Schmitt, a principal consultant with PAREXEL, discusses how the EU's Falsified Medicines Directive will affect US API production.

Pharmaceutical Technology
Volume 37, Issue 2

Q. Assuming FDA will not take any action, what does this mean for APIs originating in the US for import into the EU after July 1, 2013?

A. These APIs will be illegal and cannot be placed on the market. Given the extremely short timeline, this has already caused some NCAs, such as the United Kingdom's MHRA, to publicly voice concerns over drug-supply shortages as a result of this legislation. Of course, the EU agencies could go and inspect API manufacturers in non-EU countries, something that is happening already. The problem is the sheer number of these manufacturing sites and the limited resources for inspection. It simply isn't an option for most sites.

Q. Are there options for transitional solutions?

A. The EC has remained adamant that the law (i.e., the directive) cannot be changed and must be enforced. Nonetheless, there are many diplomatic missions underway to assure a continued drug supply in Europe. But, some companies have already taken steps to move their drug product manufacture out of Europe.

And do not forget that this directive affects not just the manufacturers, but all involved in the import and handling of the APIs, such as importers, wholesalers, and brokers. They must comply with good distribution practices (GDP) and may be inspected. It is not helpful that the new EU GDP guidelines are only expected for publication in early 2013. This leaves very little time for industry to become compliant.

Q. What do you think industry should do?

A. Industry associations are already working very hard and in collaboration with the EU authorities to gain as much clarity on what needs to be done and how. Engaging with industry associations or non-profit organizations such as the International Society for Pharmaceutical Engineers (ISPE) and the Parenteral Drug Association (PDA), next to carefully watching information coming from the agencies are the best sources of information. Unfortunately, there is very little that industry can do, but a lot that must be done by a number of agencies. At the moment, the verdict as to whether this directive proves to benefit the patients or brings about drug shortages is wide open.

More information on the organizations mentioned in this article can be found at their respective websites:


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here